UroGen Pharma (URGN) Receivables - Net (2016 - 2026)

UroGen Pharma (URGN) has 9 years of Receivables - Net data on file, last reported at $55.4 million in Q1 2026.

• Quarterly Receivables - Net rose 182.17% year-over-year to $55.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.4 million (up 182.17% YoY) and the FY2025 annual result came in at $33.1 million, up 62.95% from the prior year.
• Receivables - Net advanced to $55.4 million in Q1 2026, from $33.1 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $55.4 million in Q1 2026 to a low of $9.4 million in Q3 2022.
• A 5-year average of $18.9 million and a median of $15.5 million in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2025 — Receivables - Net dropped 13.59% — and 2026, when it surged 182.17%.
• Tracing URGN's Receivables - Net over 5 years: stood at $12.7 million in 2022, then advanced by 21.56% to $15.4 million in 2023, then jumped by 31.46% to $20.3 million in 2024, then surged by 62.95% to $33.1 million in 2025, then soared by 67.5% to $55.4 million in 2026.
• The last three Receivables - Net figures came in at $55.4 million (Q1 2026), $33.1 million (Q4 2025), and $19.7 million (Q3 2025), per Business Quant data.